Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole
- 1 October 1998
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 12 (10) , 1027-1032
- https://doi.org/10.1046/j.1365-2036.1998.00406.x
Abstract
Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 system, and linear pharmacokinetics. The recommended oral dose for treatment of acid-related diseases is 40 mg. Using a randomized, crossover study design we compared the ability of 40 mg oral and intravenous pantoprazole to elevate the intragastric pH in healthy volunteers (n = 20, 'per protocol'), during two treatment phases. The duration of each phase was 5 days. Pantoprazole 40 mg was administered once daily either as a tablet or as an intravenous injection. A 24 h pHmetry was used to record the intragastric pH on day 5 of each regimen; this was compared to the baseline curve obtained before each study period. The calculated 90% confidence intervals (90% CI) represent the mean difference in the intragastric pH, attained after intravenous or oral administration. The predefined equivalence range for the 90% CI was +/- 20% for the percentage time at which the gastric pH was at least pH 3 or 4 and +/- 1 unit for the median pH. Pantoprazole was well tolerated during both treatment phases. The mean of the 24 h median pH was 3.3 and 3.1 for the intravenous and oral treatments, respectively; the corresponding differences were 0.2 (90% CI: - 0.03 to 0.44). For the mean percentage time at which the pH was 3 or above, the respective calculated values were 57% and 51%, with a difference between the two administration routes of only 5.7% (90% CI: 1.8 to 9.6). At an intragastric pH of 4 or above, the mean percentage time was 420% and 38% following intravenous and oral treatment, respectively, with a difference between the treatment routes of only 4.4% (90% CI: 0.6 to 8.3). These results imply that the two formulations of pantoprazole can be assumed to be equipotent. Hence, the intravenous formulation of pantoprazole could be considered as an alternative route of administration.Keywords
This publication has 12 references indexed in Scilit:
- 24‐Hour Recording of Intragastric pH in Clinical Trials: Preconditions, Methodology, and Standardization StrategiesThe Journal of Clinical Pharmacology, 1997
- Twenty‐four‐hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.Alimentary Pharmacology & Therapeutics, 1996
- PantoprazoleDrugs, 1996
- The continuing development of proton pump inhibitors with particular reference to pantoprazoleAlimentary Pharmacology & Therapeutics, 1995
- Drugs for pH control in upper gastrointestinal bleedingAlimentary Pharmacology & Therapeutics, 1995
- Appropriate Acid Suppression for the Management of Gastro-Oesophageal Reflux DiseaseDigestion, 1992
- The Pharmacokinetics of Single and Repeated Once-Daily Doses of 10, 20 and 40mg Omeprazole as Enteric-Coated GranulesClinical Drug Investigation, 1991
- Is there an optimal degree of acid suppression for healing of duodenal ulcers?Gastroenterology, 1990
- Single intravenous administration of the H+, K+‐ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in manAlimentary Pharmacology & Therapeutics, 1990
- Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.Gut, 1988